MDP — Medexus Pharmaceuticals Cashflow Statement
0.000.00%
Last trade - 00:00- CA$101.61m
- CA$119.63m
- $108.33m
- 63
- 93
- 52
- 80
Annual cashflow statement for Medexus Pharmaceuticals, fiscal year end - March 31st, USD millions except per share, conversion factor applied.
2021 March 31st | 2022 March 31st | 2023 March 31st | 2024 March 31st | 2025 March 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -28.3 | -2.88 | 1.22 | -0.214 | 2.25 |
| Depreciation | |||||
| Amortisation | |||||
| Deferred Taxes | |||||
| Non-Cash Items | 32 | -8.49 | 7.43 | 12.2 | 8.99 |
| Unusual Items | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | -0.688 | 4.05 | -16.2 | 0.921 | 5.62 |
| Change in Accounts Receivable | |||||
| Change in Inventories | |||||
| Change in Prepaid Expenses | |||||
| Change in Other Assets | |||||
| Change in Payable / Accrued Expenses | |||||
| Change in Other Liabilities | |||||
| Other Operating Cash Flow | |||||
| Cash from Operating Activities | 5.04 | -1.18 | -1.44 | 18.7 | 24 |
| Capital Expenditures | -10.8 | -7.71 | -0.362 | -0.266 | -2.73 |
| Purchase of Fixed Assets | |||||
| Purchase / Acquisition of Intangibles | |||||
| Other Investing Cash Flow Items | -0.949 | -0.482 | -1.36 | -3.21 | -3.27 |
| Acquisition of Business | |||||
| Other Investing Cash Flow | |||||
| Cash from Investing Activities | -11.7 | -8.2 | -1.72 | -3.48 | -6 |
| Financing Cash Flow Items | -3.93 | -3.07 | -4.33 | -4.25 | -4.27 |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 18.7 | 0.663 | 6.41 | -23 | 0.796 |
| Foreign Exchange Effects | |||||
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | 13.5 | -8.69 | 3.05 | -7.81 | 18.7 |